|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 |
|
| |||||||||||||||||||||||||||||
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. | SEC 1474 (9-02) |
1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Reporting Owner Name / Address | Relationships | |||
Director | 10% Owner | Officer | Other | |
Seabrooke Christopher Stefan 4 COMMERCE SQUARE 39 RIVONIA ROAD SANDHURST, SANDTON GAUTENG, T3 2196 |
X |
/s/ Herman G. Kotz?, Attorney-in-Fact for Christopher Stefan Seabrooke | 09/22/2017 | |
**Signature of Reporting Person | Date |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
(1) | The common stock sold includes (i) 1,959 shares which were part of an original grant of 5,877 restricted shares, (ii) 4,987 shares which were part of an original grant of 7,481 restricted shares, (iii) 15,000 shares which were part of an original grant of 15,000 restricted shares, and (iv) 2,587 shares which were part of an original grant of 2,587 restricted shares. Each of the aforementioned restricted shares was originally set to vest over a three-year period. After the end of fiscal 2017, the board amended the terms of the outstanding awards to immediately and all future awards would vest one-year after the date of grant. As a result of this amendment, all shares held at June 30, 2017 were fully-vested. |
(2) | Sale prices for the transactions reported here range from $9.76 to $9.89. Full information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or its shareholders upon request. |